http://angiogenesis-inhibitors.....com/artificial-gene
The Japanese Osteoporosis Intervention Trial protocol number 4 (JOINT-04) trial is a multi-center, open-labeled, blinded endpoints, head-to-head randomized trial of minodronate and raloxifene. Ambulatory elderly females with weakening of bones (age, 60 years) had been randomly allotted to the raloxifene or minodronate group by main registration. The co-primary endpoints included any one of osteoporotic fractures (vertebral, humeral, femoral, and radi